

PROVIDER NOTIFICATION OF RETAIL DRUG POLICY CRITERIA CHANGE			
Drug(s) Impacted	CRITERIA CHANGE	EFFECTIVE DATE	Formulary
Auvelity	Adds coverage for agitation associated with dementia due to Alzheimer's disease. Adds limitation prohibiting PRN use for agitation associated with dementia due to Alzheimer's disease. Adds PA documentation requirements for Alzheimer's disease-related agitation. Adds initial approval criteria for Alzheimer's disease-related agitation. Adds continuation criteria for Alzheimer's disease-related agitation. Expands exclusions to include non-covered indications beyond MDD and Alzheimer's disease-related agitation. Adds exclusion for PRN use in Alzheimer's disease-related agitation.	10/15/2026	Standard
Dupixent	Adds documentation requirements for initial and continuation requests across all covered indications. Adds indication-specific prescriber specialty requirements. Expands Chronic Spontaneous Urticaria (CSU) eligibility from age ≥ 12 years to age ≥ 2 years. Updates CSU step therapy to require inadequate response to up-dosed second-generation antihistamine therapy. Adds coverage criteria for Allergic Fungal Rhinosinusitis (AFRS). Adds continuation criteria for AFRS requiring documented positive clinical response.	10/15/2026	Standard Metallic